Christopher Bunka - 26 Apr 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Signature
/Chris Bunka/
Issuer symbol
LEXX
Transactions as of
26 Apr 2024
Transactions value $
$0
Form type
4
Date filed
10 May 2024, 16:44
Previous filing
30 Oct 2023
Next filing
10 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 274K 26 Apr 2024 Direct
holding LEXX common shares 254K 26 Apr 2024 Private Holding Company

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +49.5K +37.79% $0.00 181K 26 Apr 2024 Common Shares 49.5K $2.36 Direct
holding LEXX Warrants 6.67K 26 Apr 2024 Common Shares 6.67K $10.50 Private Holding Company
holding LEXX Stock Options 32.7K 26 Apr 2024 Common Shares 26K $3.00 Direct F1
holding LEXX Stock Options 56K 26 Apr 2024 Common Shares 23.3K $3.00 Direct F2
holding LEXX Stock Options 71K 26 Apr 2024 Common Shares 15K $3.00 Direct F3
holding LEXX Stock Options 101K 26 Apr 2024 Common Shares 30K $2.91 Direct
holding LEXX Stock Options 131K 26 Apr 2024 Common Shares 30K $1.15 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.83 pursuant to shareholder approval received on May 9, 2023
F2 Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023